Animalcare has announced the UK and Ireland launch of Vitofyllin, a central nervous system stimulant for older dogs suffering from dullness, poor demeanour and unwillingness to exercise.

The launch of Vitofyllin is the result of a collaboration between Animalcare and three European partners.

The company says the project has enhanced its in-house expertise because the active ingredient for the product was unavailable in the market and had to be contract synthesised, a first for a new product development at Animalcare. The regulatory procedure was also the first time a bioequivalence bio-waiver had been successfully applied for and obtained in Europe. This made the development quicker, more cost effective, less risky and importantly avoided the need for animal testing.

Animalcare says that as in previous years, it has set itself a target of launching four new veterinary medicines during the year. This launch is the first of those planned for the new financial year.

Stephen Wildridge, CEO of Animalcare Group, said: "We are very pleased to be able to add our new generic medicine Vitofyllin to our range of licensed veterinary medicines. The launch represents the culmination of the biggest development project undertaken by Animalcare and is the product of successful collaboration with members of our European partnership network."

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.